| Dr Thomas E Schmidt, MD | |
|
375 Dixmyth Avenue, Cincinnati, OH 45220-2475 | |
| (513) 872-2432 | |
| (513) 872-8857 |
| Full Name | Dr Thomas E Schmidt |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 37 Years |
| Location | 375 Dixmyth Avenue, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053378307 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35061534S (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Group Practice Inc | 1254245137 | 361 |
News Archive
The Obama administration is proposing regulatory changes to clarify who is prohibited from owning a gun for mental health reasons and to tighten background checks. In the meantime, lawmakers consider increasing mental health funding after the Sandy Hook massacre.
Therapists have long known that people who've had a traumatic experience feel the need to talk about what they've been through. This process is called 'social sharing' and can take place for days, weeks, months or years after the event.
A team of researchers has discovered a new chemical reaction for producing one of the four nucleotides, or building blocks, needed to build DNA.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
› Verified 1 days ago
| Entity Name | Anesthesia Group Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417951948 PECOS PAC ID: 1254245137 Enrollment ID: O20031114000492 |
News Archive
The Obama administration is proposing regulatory changes to clarify who is prohibited from owning a gun for mental health reasons and to tighten background checks. In the meantime, lawmakers consider increasing mental health funding after the Sandy Hook massacre.
Therapists have long known that people who've had a traumatic experience feel the need to talk about what they've been through. This process is called 'social sharing' and can take place for days, weeks, months or years after the event.
A team of researchers has discovered a new chemical reaction for producing one of the four nucleotides, or building blocks, needed to build DNA.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas E Schmidt, MD Po Box 640738, Cincinnati, OH 45264-0738 Ph: (800) 754-9764 | Dr Thomas E Schmidt, MD 375 Dixmyth Avenue, Cincinnati, OH 45220-2475 Ph: (513) 872-2432 |
News Archive
The Obama administration is proposing regulatory changes to clarify who is prohibited from owning a gun for mental health reasons and to tighten background checks. In the meantime, lawmakers consider increasing mental health funding after the Sandy Hook massacre.
Therapists have long known that people who've had a traumatic experience feel the need to talk about what they've been through. This process is called 'social sharing' and can take place for days, weeks, months or years after the event.
A team of researchers has discovered a new chemical reaction for producing one of the four nucleotides, or building blocks, needed to build DNA.
The acquisition of Unetixs Vascular's detection and diagnostics products complements and strengthens the existing Opto Circuits (I) Ltd. product portfolio investment in Criticare Systems, Inc.'s vital signs monitoring line and pulse oximetry sensors. Unetixs Vascular is a leader in products aimed at the detection of peripheral arterial disease (PAD), a condition that is affecting a growing portion of the population in both the developed world and in emerging economies.
Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.
› Verified 1 days ago
Alexander Topala, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman St, Mail Location 0796, Cincinnati, OH 45219 Phone: 513-584-1000 | |
Eli Cianciolo, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4805 Montgomery Rd, Suite 210, Cincinnati, OH 45212 Phone: 513-791-6400 Fax: 513-791-5306 | |
Angel Joshua Pagan, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-558-6356 | |
Dave Wright, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-585-2422 Fax: 513-585-3245 | |
Robert S Jacob, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2139 Auburn Ave, Cincinnati, OH 45219 Phone: 513-672-3309 Fax: 513-672-3323 | |
Mr. Kun Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 4777 E Galbraith Rd, Cincinnati, OH 45236 Phone: 513-686-3000 | |
Nalini Tandon, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 7500 State Rd, Anethesia Intensive Care Consultants Inc, Cincinnati, OH 45255 Phone: 859-341-7246 Fax: 859-341-7867 |